Insmed INSM

Biotechnology, Healthcare

$93.39

−1.76%

Market cap: $20.4B
PE: n/m; a loss over the last year
Forward PE: n/m; a loss over the last year
Price to sales: 17.9×
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: $1.1B; +186% on a year ago
Net margin: −76.9%
Free cash flow yield: −4.0%

Insmed trades at 17.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.1B over the last twelve months, up 186% on a year earlier with a −77% net margin.

Charts

Financials

Income statement for INSM, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
	$79.1M+17%	$83.7M+41%	$75.5M+16%	$90.3M+17%	$93.4M+18%	$104.4M+25%	$92.8M+23%	$107.4M+19%	$142.3M+52%	$263.8M+153%	$306M+230%	$425.5M+296%
Cost of revenue	$16.7M+24%	$18.4M+41%	$17.5M+26%	$21M+26%	$21.2M+27%	$26.2M+42%	$21.3M+22%	$28.1M+34%	$29.4M+39%	$44.2M+69%	$47.4M+123%	$67.2M+139%
Gross profit	$62.4M+15%	$65.3M+41%	$58M+13%	$69.4M+14%	$72.3M+16%	$78.3M+20%	$71.5M+23%	$79.3M+14%	$113M+56%	$219.6M+181%	$258.5M+261%	$358.3M+352%
R&D	$109.1M+9%	$137M+10%	$121.1M−5%	$146.7M−26%	$150.8M+38%	$179.7M+31%	$152.6M+26%	$177.2M+21%	$186.4M+24%	$254.9M+42%	$209.5M+37%	$210M+19%
SG&A	$90.6M+20%	$89.5M+22%	$93.1M+17%	$106.6M+26%	$118.9M+31%	$142.5M+59%	$147.5M+59%	$154.8M+45%	$186.4M+57%	$212.5M+49%	$247.3M+68%	$247.5M+60%
	−$147.7M+16%	−$178.3M+18%	−$145.5M−2%	−$288.9M+23%	−$213.4M+45%	−$230.4M+29%	−$248.1M+71%	−$312.9M+8%	−$366M+72%	−$319.7M+39%	−$153.3M−38%	−$1.5M−100%
Interest expense	$20.3M+505%	$20.8M+26%	$21M+5%	$21.3M+3%	$21.1M+4%	$21.6M+4%	$21.6M+3%	$21.2M−0%	$20.4M−3%	$20.6M−4%	$20.1M−7%	$20.3M−5%
Pre-tax income	−$158.4M+21%	−$185.1M+16%	−$156.5M−2%	−$299.8M+23%	−$219.5M+39%	−$234.3M+27%	−$255.7M+63%	−$320.4M+7%	−$368.7M+68%	−$326.9M+40%	−$162.1M−37%	−$11.4M−97%
	$544K+46%	$998K+698%	$589K+22%	$838K+58%	$1M+86%	$1.3M+27%	$912K+55%	$1.2M+48%	$1.3M+30%	$1.6M+23%	$1.5M+61%	$1.9M+50%
Net income	−$158.9M+21%	−$186.1M+16%	−$157.1M−2%	−$300.6M+23%	−$220.5M+39%	−$235.5M+27%	−$256.6M+63%	−$321.7M+7%	−$370M+68%	−$328.5M+40%	−$163.6M−36%	−$13.2M−96%
	−$1.11+2%	−$1.28+6%	−$1.06−9%	−$1.94+9%	−$1.27+14%	−$1.32+3%	−$1.42+34%	−$1.70−12%	−$1.75+38%	−$1.54+17%	−$0.76−47%	−$0.06−97%
	142.9M+18%	144.8M+9%	148.5M+9%	154.7M+13%	173.7M+22%	179M+24%	180.9M+22%	189.3M+22%	211.8M+22%	213.6M+19%	215.5M+19%	217.4M+15%

Gross profit: 34 periods, Q1 FY17 to Q2 FY26: not printed by the filing, worked out from its own lines.

Net income: 6 periods, Q1 FY13 to Q3 FY14: not printed by the filing, worked out from its own lines.

EPS, diluted: 8 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 4 periods, Q3 FY10 to Q1 FY12: not printed by the filing, worked out from its own lines. 16 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Estimates

Next earnings report: Oct 29, 2026.

Quarter	Revenue	Range	EPS	Range	Analysts
Q3 FY26	$499.1M	$493.8M to $512.5M	−$0.39	−$0.51 to −$0.15	13
Q4 FY26	$573.9M	$553.2M to $605.9M	−$0.32	−$1.14 to $0.12	11
Q1 FY27	$685.8M	$660.3M to $736.4M	−$0.15	−$0.17 to −$0.14	4
Q2 FY27	$673.7M	$648.7M to $723.5M	$0.12	$0.12 to $0.13	4
Q3 FY27	$733.7M	$706.4M to $787.9M	$0.30	$0.29 to $0.33	7
Q4 FY27	$795.5M	$765.9M to $854.3M	$0.45	$0.43 to $0.50	4
Q1 FY28	$826.4M	$795.6M to $887.4M	$0.35	$0.33 to $0.38	5
Q2 FY28	$916.3M	$882.2M to $983.9M	$0.60	$0.57 to $0.65	6

Peers

Companies in Biotechnology nearest Insmed's size, closest first.

Company	Market cap	PE	Its 10y median PE	Fwd PE	P/S	Revenue growth	Net margin
INSMInsmed	$20.4B	n/m	n/a	n/m	17.9×	+186%	−76.9%
INCYIncyte	$23.5B	14.7×	36.9×	49.5×	4.0×	+27%	27.7%
UTHRUnited Therapeutics	$25.2B	21.0×	14.1×	22.0×	8.0×	+2%	41.6%
EXELExelixis	$16B	20.3×	22.8×	n/m	6.6×	+9%	35.3%
NBIXNeurocrine Biosciences	$14.5B	20.9×	42.8×	n/m	4.3×	+34%	20.9%
HALOHalozyme Therapeutics	$14.3B	37.5×	21.3×	n/m	8.6×	+41%	24.9%
ALNYAlnylam Pharmaceuticals	$30B	37.8×	69.2×	26.7×	6.2×	+95%	16.8%
TECHBIO-TECHNE	$11.4B	63.1×	61.6×	n/m	9.4×	−0%	15.0%
RGENRepligen	$10B	242×	120×	n/m	12.7×	+16%	5.3%
ONCBeOne Medicines	$42.9B	67.6×	68.4×	48.1×	7.0×	+34%	10.7%
KRYSKrystal Biotech	$9.2B	39.0×	42.7×	n/m	20.9×	+23%	54.8%
Peer median	$15.2B	37.6×	42.8×	37.4×	7.5×	+25%	22.9%